Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Canopy Growth Corp (CGC) vs Goldman Sachs Group Inc (GS) Price & Performance

Canopy Growth CorpTrade
Goldman Sachs Group IncTrade

Price performance (Past 24H)

Key statistics

Canopy Growth Corp vs Goldman Sachs Group Inc — how do they compare? Canopy Growth Corp trades at $0.97 (market cap $398.46M), while Goldman Sachs Group Inc trades at $1,143.5 (market cap $336.31B). The key difference: Goldman Sachs Group Inc is far larger — about 844× Canopy Growth Corp's market cap, and Goldman Sachs Group Inc pays a 1.58% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.

CGCGS
Market Cap
$398.46M$336.31B
Sector
HealthFinancials
52-Week High
$1.92$1.14K
52-Week Low
$0.86$700.41
Enterprise Value
$337.90M
Volume
2,592,735
Dividend Yield
1.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Canopy Growth Corp

Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.

The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.

Goldman Sachs Group Inc

Goldman Sachs (GS) trades at $1,045.91, down 0.88% on the day, with a bullish technical outlook and strong earnings momentum after three consecutive quarterly beats. Revenue grew to $58.28B in 2025, with net income reaching $17.18B and a net margin of 29.89%. The company is positioned to benefit from near-record M&A activity and high-profile IPOs like Anthropic, with CEO David Solomon noting investor 'greed mode' amid robust liquidity. Analysts maintain a consensus price target of $1,080 with 40% buy ratings.

The stock offers upside to the consensus target, supported by earnings growth and investment banking tailwinds, but faces risks from volatile cash flows, high leverage, and macroeconomic sensitivity. Institutional sentiment is cautiously optimistic, though negative operating cash flow and debt levels warrant monitoring for sustained shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Canopy Growth Corp

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.

Read more on CGC

About Goldman Sachs Group Inc

The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.

Read more on GS